Inosine pranobex in the treatment of herpes simplex virus type 1 and type 2 infections Review article
Article Sidebar
Published:
Dec 31, 2012
Keywords:
inosine pranobex, viral infections, HSV-1, HSV-2
Main Article Content
Abstract
Inosine pranobex is a well-known medication used for approximately forty years. It is available in two pharmaceutical forms: tablets and syrup. The indications for its use are especially viral skin and mucous membranes infections caused by: HSV-1, HSV-2, VZV and other viral infections (i.e. subacute sclerosing panencephalitis, genital warts, hepatitis B, upper respiratory tract infection and HIV). Because of its immunomodulating effect, inosine pranobex is also useful as adjuvant therapy in immunocompromised patients. In this paper, with reference to the available literature data, the author emphasized the benefits of this medication in frequent, recurrent and burdensome herpes viral infection of 1 and 2 type.
Article Details
How to Cite
Matusiak, Łukasz. (2012). Inosine pranobex in the treatment of herpes simplex virus type 1 and type 2 infections. Medycyna Faktow (J EBM), 5(4(17), 28-31. Retrieved from https://www.journalsmededu.pl/index.php/jebm/article/view/2438
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Walkowiak H., Żaba R.: Epidemiologia zakażeń. W: Opryszczka, półpasiec, ospa wietrzna. Żaba R. (red.). Termedia, Poznań 2011.
2. Buxxbaum S., Grees M., Gross G. et al.: Epidemiology of herpes simplex virus type 1 and 2 in Germany: what has changed? Med. Microbiol. Immunol. 2003; 192: 177-181.
3. Malvy D., Halioua B., Lancon F. et al.: Epidemiology of genital herpes simplex virus infections in a community-based sample in France: results of the Herpimax study. Sex. Transm. Dis. 2005; 32: 499-505.
4. Smith J.S., Rosinska M., Trzcinska A. et al.: Type specific seroprevalence of HSV-1 and HSV-2 in four geographical regions of Poland. Sex. Transm. Infect. 2006; 82: 159-163.
5. Laffert W.E.: The changing epidemiology of HSV-1 and HSV-2 and implications for serological testing. Herpes 2002; 9: 51-55.
6. Umene K., Kawana T.: Molecular epidemiology of herpes simplex virus type 1 genital infection in association with clinical manifestations. Arch. Virol. 2000; 145: 505-522.
7. Figlerowicz M.: Wirusy opryszczki – przebieg kliniczny infekcji i terapia. Przew. Lek. 2005; 6: 96-103.
8. Wysocki J., Salamon-Słowińska D.: Zakażenie wirusami Herpes simplex – postacie kliniczne i ich leczenie. Zakażenia 2003; 3: 62-67.
9. Braun-Falco O., Plewig G., Wolff H.H., Burgdorf W.H.C.: Dermatologia. Tom I. Czelej, Lublin 2002: 59-73.
10. Mroczkowski T.F., Teofoli P., Ferranti G. et al.: Opryszczka narządów płciowych. W: Choroby przenoszone drogą płciową. Mroczkowski T.F. (red.). Czelej, Lublin 2006: 183-206.
11. Aga I.E., Hollier L.M.: Managing genital herpes infections in pregnancy. Women’s Health 2009; 5: 165-174.
12. Zajac J., Harrington L.E.: Immune response to viruses: cell-mediated immunity. Encyclopedia of Virology, Third Edition 2008; 3: 70-77.
13. Ohnishi H., Kosuzume H., Inaba H. et al.: Mechanism of host defence suppression induced by viral infection: mode of action of inosiplex an antiviral agent. Infection and Immunity 1982; 1: 243-50.
14. Talbot D.J., Menday A.P.: Inosine pranobex in mucocutaneous herpes. Lancet 1985; 325: 877.
15. Galli M., Lazzarin A., Moroni M., Zanussi C.: Inosiplex in recurrent herpes simplex infections. Lancet 1982; 2: 331-332.
16. Galli M., Lazzarin A., Moroni M., Zanussi C.: Treatment of recurrent viral infectious diseases by methisoprinol. W: Immunomodulation: New frontiers and advances. Frudenberg H.H., Whitten H.D., Ambrogi F. (red.). Plenum Press, New York 1984: 375.
17. Corey L., Chiang W.T., Reeves W.C. et al.: Effect of Isoprinosine on the cellular immune response in initial genital herpes virus infection. Abstract. Clin. Res. 1979; 27: 41A.
18. Campoli-Richards D.M., Sorkin E.M., Heel R.C.: Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1986; 32: 383-424.
19. Miller R.D.: Safety and efficacy of inosine pranobex in recurrent genital herpes simplex infections. Presented at Mary’s Hospital, London 1984.
20. Lawrence A.G.: Inosine pranobex in treatment of recurrent herpes genitalis infection. Abstract. 2nd World Congerss on Sexually Transmited Diseases, Paris, 25-29 June, 1986.
21. Bunta S.: Report of clinical testing of Isoprinosine tablets in herpes simplex infections. Int. J. Immunopharmacol. 1980; 2: 208.
2. Buxxbaum S., Grees M., Gross G. et al.: Epidemiology of herpes simplex virus type 1 and 2 in Germany: what has changed? Med. Microbiol. Immunol. 2003; 192: 177-181.
3. Malvy D., Halioua B., Lancon F. et al.: Epidemiology of genital herpes simplex virus infections in a community-based sample in France: results of the Herpimax study. Sex. Transm. Dis. 2005; 32: 499-505.
4. Smith J.S., Rosinska M., Trzcinska A. et al.: Type specific seroprevalence of HSV-1 and HSV-2 in four geographical regions of Poland. Sex. Transm. Infect. 2006; 82: 159-163.
5. Laffert W.E.: The changing epidemiology of HSV-1 and HSV-2 and implications for serological testing. Herpes 2002; 9: 51-55.
6. Umene K., Kawana T.: Molecular epidemiology of herpes simplex virus type 1 genital infection in association with clinical manifestations. Arch. Virol. 2000; 145: 505-522.
7. Figlerowicz M.: Wirusy opryszczki – przebieg kliniczny infekcji i terapia. Przew. Lek. 2005; 6: 96-103.
8. Wysocki J., Salamon-Słowińska D.: Zakażenie wirusami Herpes simplex – postacie kliniczne i ich leczenie. Zakażenia 2003; 3: 62-67.
9. Braun-Falco O., Plewig G., Wolff H.H., Burgdorf W.H.C.: Dermatologia. Tom I. Czelej, Lublin 2002: 59-73.
10. Mroczkowski T.F., Teofoli P., Ferranti G. et al.: Opryszczka narządów płciowych. W: Choroby przenoszone drogą płciową. Mroczkowski T.F. (red.). Czelej, Lublin 2006: 183-206.
11. Aga I.E., Hollier L.M.: Managing genital herpes infections in pregnancy. Women’s Health 2009; 5: 165-174.
12. Zajac J., Harrington L.E.: Immune response to viruses: cell-mediated immunity. Encyclopedia of Virology, Third Edition 2008; 3: 70-77.
13. Ohnishi H., Kosuzume H., Inaba H. et al.: Mechanism of host defence suppression induced by viral infection: mode of action of inosiplex an antiviral agent. Infection and Immunity 1982; 1: 243-50.
14. Talbot D.J., Menday A.P.: Inosine pranobex in mucocutaneous herpes. Lancet 1985; 325: 877.
15. Galli M., Lazzarin A., Moroni M., Zanussi C.: Inosiplex in recurrent herpes simplex infections. Lancet 1982; 2: 331-332.
16. Galli M., Lazzarin A., Moroni M., Zanussi C.: Treatment of recurrent viral infectious diseases by methisoprinol. W: Immunomodulation: New frontiers and advances. Frudenberg H.H., Whitten H.D., Ambrogi F. (red.). Plenum Press, New York 1984: 375.
17. Corey L., Chiang W.T., Reeves W.C. et al.: Effect of Isoprinosine on the cellular immune response in initial genital herpes virus infection. Abstract. Clin. Res. 1979; 27: 41A.
18. Campoli-Richards D.M., Sorkin E.M., Heel R.C.: Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1986; 32: 383-424.
19. Miller R.D.: Safety and efficacy of inosine pranobex in recurrent genital herpes simplex infections. Presented at Mary’s Hospital, London 1984.
20. Lawrence A.G.: Inosine pranobex in treatment of recurrent herpes genitalis infection. Abstract. 2nd World Congerss on Sexually Transmited Diseases, Paris, 25-29 June, 1986.
21. Bunta S.: Report of clinical testing of Isoprinosine tablets in herpes simplex infections. Int. J. Immunopharmacol. 1980; 2: 208.